Jefferies Initiates Q32 Bio at Buy With $29 Target on Alopecia Potential
The firm points to bempikibart in severe alopecia, a 1H 2027 Phase 3 start, and a stronger cash runway.
/ 5 items
#QTTB↓
Morgan Stanley Initiates Q32 Bio at Overweight with $34 Target — 113% Upside Potential
Morgan Stanley initiates Q32 Bio at Overweight ($34 target) as bempikibart matches JAK efficacy in alopecia areata while offering cleaner safety, less monitoring and durability.
Bempikibart Delivers Promising Hair Regrowth in Alopecia Trial, Sending Q32 Bio Stock Soaring
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.